AxoGen has patented a customizable fasciculated nerve graft that bridges nerve gaps. The graft is made by entubulating nerve fascicles in a biocompatible material, free of epineurial sheath and native extracellular matrix. This innovation allows for restoring nerve continuity of any length and diameter. GlobalData’s report on AxoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights AxoGen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AxoGen, AI-assisted MRI was a key innovation area identified from patents. AxoGen's grant share as of May 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Customizable fasciculated nerve grafts for bridging nerve gaps

Source: United States Patent and Trademark Office (USPTO). Credit: AxoGen Inc

A recently granted patent (Publication Number: US11998661B2) discloses a novel fasciculated nerve graft that consists of one or more nerve fascicles entubulated in a biocompatible material. Notably, this nerve graft is devoid of epineurial sheath and native extracellular matrix material, distinguishing it from conventional nerve grafts. The patent outlines various embodiments of the fasciculated nerve graft, including those with a single nerve fascicle or multiple nerve fascicles ranging from 2 to 20, each with diameters between 50 µm and 1 mm. Additionally, the graft can be coated with a biocompatible material and may contain growth factors, cells, or other therapeutic agents to enhance nerve regeneration.

Furthermore, the patent details a method for preparing the fasciculated nerve graft, involving the enzymatic degradation of the epineurial sheath and native extracellular matrix material in nerve tissue. This process results in the production of nerve fascicles that are free of these components, which are then encapsulated in the biocompatible entubulation material. The removal of the epineurial sheath and native extracellular matrix material is highlighted as a key feature of this invention, with the graft being suitable for use in peripheral or spinal nerve repair. The patent also emphasizes the customizable nature of the fasciculated nerve graft, allowing for variations in length, diameter, and the inclusion of additional therapeutic components to meet specific clinical needs.

To know more about GlobalData’s detailed insights on AxoGen, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.